Lantheus begins exchange offer for eligible holders

NewsGuard 100/100 Score

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that on April 8, 2011 it commenced an exchange offer for eligible holders to exchange any and all of the company's outstanding unregistered 9.75% Senior Notes due 2017. These notes were originally issued on March 21, 2011 in a transaction exempt from registration under the Securities Act of 1933, as amended, in an aggregate principal amount of $150 million. Eligible holders of these notes may exchange them for an equal principal amount of the company's registered 9.75% Senior Notes due 2017. The terms of the registered notes are substantially identical to the unregistered notes, except for transfer restrictions and registration rights relating to the unregistered notes.

The exchange offer will expire at 5:00 p.m., Eastern Time on May 9, 2011, unless extended in accordance with its terms. Exchanges of the unregistered notes must be made in accordance with the terms of the exchange offer before the exchange offer expires and may be withdrawn at any time before the exchange offer expires.

Source: Lantheus Medical Imaging, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis